Articles By Jack Cush, MD
Can Rituximab Change the Course of Interstitial Lung Disease?
Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.
Read Article
Anniversary Feature: Top 5 Most-Read Articles from 1st Year
It is important to know where you’ve been, as it will most certainly color where you are going. Hence, in honor of our 1st year anniversary, we have taken note of our most popular articles.
Read Article
RheumNow Week in Review – 22 April 2016
Watch Dr. Jack Cush cover ten highlights from this week on RheumNow.com.
Read Article
Why My Patients Sit Where They Sit
Where do your patients sit? Have you noticed they don't usually sit where you expect them to? What's up with that, and is there a psychology behind one's choice of seating? This curious observation may portend the nature of the physician-patient relationship or, at the very least, impact the layout of your next clinic.
Read Article
Vaccine Success is Limited in Rheumatoid Arthritis
Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics.
Read Article
α Defensin Control of Inflammation
Alpha defensins are released following apoptosis, necrosis, or netosis of human neutrophils. They are taken up by other cells and microbes, wherein they permeablize membranes and kill microbes and host cells. Thus, they augment the antimicrobial capacity of macrophages and at the same time inhibit the biosynthesis of proinflammatory cytokines.
Read Article
Posterior Reversible Encephalopathy in Lupus
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder with many associations or causative factors that rarely includes autoimmune disorders and lupus.
Read Article
FDA Will Review Opioid Analgesic Use and REMS Programs for Pediatric Pain Patients
Amidst a stringent regulatory environment, and with the rising use and abuse of narcotics and increasing regulation limiting narcotic analgesic use, the FDA approved (August 2015) the use of extended-release oxycodone in children (11 to 16 years old) with severe, "around-the-clock" pain
Read Article
BeST Trial and 10-Year Outcomes of Four Treatment Strategies
Markusse and investigators from The Netherlands have reported their 10 year results of treating early rheumatoid arthritis (RA) patients using targeted treatment strategies.
Read Article
Osteoporotic Fractures at Higher Risk for Subsequent Fractures
Harvey and coworkers reported the results of subjects followed in the Reykjavik study, demonstrating that a first osteoporotic fracture was followed by an increased risk for a second fracture, both immediately and over time.
Read Article
